Volt - ACDC

Ultime notizie per Tema Electrification ETF (NASDAQ:VOLT)

Volt Information Sciences

Industrials

Utilities

Technology

Other

Under normal circumstances, the Tema Electrification ETF (the Fund) seeks to achieve its investment objective by investing at least 80 precent of its net assets, which include borrowings for investment purposes, common and preferred stocks of publicly listed companies that are directly or indirectly economically tied to global electrification. A company is considered to be economically tied to the electrification theme if it generates 50 percent of its revenue from a combination of (i) the supply of electrification and/or power generation raw materials, including natural resources, (ii) the supply of electrification and/or power generation equipment, software and associated services, such as grid, transmission and distribution equipment, software such as Uninterruptable Power Supplies, and hardware such as turbines, and (iii) the storage of electricity. This includes, but is not limited to, firms that operate in the following sub-industries: electrical equipment, energy, industrial machinery supplies and components, distributors, electric, gas and renewable utilities, and construction and engineering companies.

Nextera Energy Inc.

Ge Vernova

Itron Inc

Oge Energy Corp.

Bel Fuse Inc Cl B

Entergy Corp.

American Electric Power Co. Inc.

Hubbell Inc. Class B

Quanta Services Inc

Pinnacle West Capital Corp.

Tema Electrification ETF

VOLT INFORMATION SCIENCES IN COM

VOLTA FINANCE LTD by Volta Finance Ltd.

VOLTABOX AG INH O N by VOLTABOX AG

VOLTAIC STRATEGIC RES LTD by VOLTAIC STRATEGIC RES LTD.

VOLT CARBON TECHNOLOGIES by Volt Carbon Technologies Inc.

Volt Carbon Technologies Inc

Volt Group Ltd

Volt Lithium Corp

Volt Resources Ltd

VOLTAGE METALS CORP by VOLTAGE METALS CORP.

Voltage Metals Corp

Voltalia SA

WIIM

HYLN

Hyliion Holdings shares are trading lower after the company reported worse-than-expected Q1 financial results.

Wells Fargo analyst Ike Boruchow maintains Ralph Lauren (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RL#NYSE">RL</a>) with a Overweight and raises the price target from $240 to $275.

News

Price Target

Analyst Ratings

Wells Fargo Maintains Overweight on Ralph Lauren, Raises Price Target to $275

ETOR

Trading Halt: Halt status updated at 10:10:00 AM ET: Quotation Resumption: IPO Security - Released for Quotation

<a href="https://www.youtube.com/watch?v=nUqZzzZ6d2o">https://www.youtube.com/watch?v=nUqZzzZ6d2o</a>

General

President Trump Says Discussed Russia And Ukraine With Qatar Emir, Iran Too; Says Iran Situation Will Work Out; Says Boeing Agreement Is For Over $200B

Wells Fargo analyst Ike Boruchow maintains PVH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PVH#NYSE">PVH</a>) with a Equal-Weight and raises the price target from $85 to $100.

Wells Fargo Maintains Equal-Weight on PVH, Raises Price Target to $100

Zevra Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZVRA#NASDAQ">ZVRA</a>) shares are trading higher by 3.1% to $8.11 Wednesday morning after the company reported better-than-expected first-quarter financial results.
What To Know: The rare disease-focused biotech <a href="https://www.benzinga.com/pressreleases/25/05/g45390130/zevra-reports-first-quarter-2025-financial-results-and-corporate-update">posted</a> a net loss of 6 cents per share, beating analyst estimates of a 20 cent loss and marking a sharp improvement from last year's 40 cent loss per share. Revenue soared to $20.4 million—up nearly 500% year-over-year—driven primarily by sales of MIPLYFFA and reimbursements for arimoclomol.
Read Also: <a href="https://www.benzinga.com/general/biotech/25/05/45407486/novo-nordisk-inks-22-billion-deal-with-septerna-to-develop-oral-weight-loss-and-diabetes-drugs">Novo Nordisk Inks $2.2 Billion Deal With Septerna To Develop Oral Weight Loss And Diabetes Drugs</a>
CEO Neil F. McFarlane emphasized the company's transformation into a commercial-stage, patient-centric therapeutics firm, with a strategic focus on expanding market access for MIPLYFFA and OLPRUVA.
Zevra says the company also continues to <a href="https://www.benzinga.com/pressreleases/25/05/g45390130/zevra-reports-first-quarter-2025-financial-results-and-corporate-update">advance its pipeline</a>, enrolling more patients in the Phase 3 trial of celiprolol for Vascular Ehlers-Danlos Syndrome and planning to file a European marketing application for MIPLYFFA in the second half of 2025.
Zevra highlighted that the company&#8217;s financial position is bolstered by $150 million in gross proceeds from the recent sale of a Priority Review Voucher, bringing its post-quarter-end cash position to $217 million.
Read Also: <a href="https://www.benzinga.com/trading-ideas/movers/25/05/45405793/red-cat-holdings-stock-is-ripping-higher-wednesday-whats-going-on">Red Cat Holdings Stock Is Ripping Higher Wednesday: What&#8217;s Going On?</a>
<h2 class="wp-block-heading">How To Buy ZVRA Stock</h2>
By now you're likely curious about how to participate in the market for Zevra Therapeutics &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy &#8220;fractional shares,&#8221; which allows you to own portions of stock without buying an entire share.
In the case of Zevra Therapeutics, which is trading at $8.47 as of publishing time, $100 would buy you 11.81 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to &#8220;go short&#8221; a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, ZVRA has a 52-week high of $9.76 and a 52-week low of $4.20.

ZVRA

Zevra Therapeutics (ZVRA) Stock Jumps on Strong Q1 Results: What's Going On?

Wells Fargo analyst Ike Boruchow maintains Nike (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) with a Equal-Weight and raises the price target from $55 to $60.

Wells Fargo Maintains Equal-Weight on Nike, Raises Price Target to $60

NU stock has given up its prior loss. Nu Holdings shares were trading lower after the company reported worse-than-expected Q1 financial results.

B of A Securities analyst Lorraine Hutchinson maintains Under Armour (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UAA#NYSE">UAA</a>) with a Neutral and lowers the price target from $10 to $8.

B of A Securities Maintains Neutral on Under Armour, Lowers Price Target to $8

Tower Semiconductor Ltd&nbsp;(NASDAQ:&nbsp;TSEM)&nbsp;reported <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/g45402250/tower-semiconductor-reports-2025-first-quarter-financial-results" rel="noreferrer noopener">fiscal first-quarter</a> results on Wednesday. The company reported a quarterly revenue growth of 9% year-on-year to $358.17 million, compared to the&nbsp;analyst consensus estimate of $358.15 million.
The Israel-based contract chipmaker&#8217;s adjusted EPS of 45 cents beat the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">analyst consensus estimate</a> of 38 cents.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/02/43636975/tower-semiconductor-adapts-to-nvidias-architectural-shift-analyst-sees-growth-in-ai-optical-networks" rel="noreferrer noopener">Tower Semiconductor Adapts To Nvidia&#8217;s Architectural Shift, Analyst Sees Growth In AI Optical Networks</a>
Gross profit was $73.17 million, up 0.8% Y/Y.&nbsp;The margin declined to 20.4% from 22.2% Y/Y. Operating profit of $32.9 million decreased 3.2%&nbsp;Y/Y.
Gross and operating profits remained similar since the positive impact of the $31 million revenue increase was offset by the fixed costs of the new 300mm Agrate facility, as previously disclosed. During the <a href="https://www.benzinga.com/25/02/43593383/tower-semiconductor-q4-earnings-beats-eps-estimates-expands-ai-chip-production-for-2025-growth" target="_blank" rel="noreferrer noopener">fourth quarter of 2024</a>, the company discontinued the lower margin legacy of 150mm flows in Fab1, with the last Fab-outs occurring in January 2025.
During the quarter, the company generated $93.92 million in operating cash flow and held $1.18 billion in cash and equivalents.
CEO Russell Ellwanger said, &#8220;Tower Semiconductor delivered continued record revenue in RF infrastructure, including SiPho and SiGe. Throughout the year, it targeted further revenue growth of these technologies, increases in its high-voltage 200mm power management business, and higher revenue levels in its sensors business. Additionally, it entered a new market for Tower, namely envelope trackers, using its 300mm technology platform.&#8221;
Outlook: Tower Semiconductor expects second-quarter revenue of $353.4 million to $390.6 million compared to the&nbsp;$371.3 million <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">analyst consensus estimate</a>.
TSEM Price Action: TSEM stock is down 1.37% to $39.54 at the last check on Wednesday.&nbsp;
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/tech/25/05/45320459/nvidia-apple-face-bigger-risks-from-china-trade-talks-than-any-boost-from-uk-deal-analyst-says" target="_blank" rel="noreferrer noopener">Nvidia, Apple Face Bigger Risks From China Trade Talks Than Any Boost From UK Deal, Analyst Says</a></li>
</ul>
Image by T. Schneider via Shutterstock

Earnings

Guidance

Movers

Tech

TSEM

Tower Semiconductor Stock Dips Despite Q1 Revenue Growth As Margins Squeeze

Wells Fargo analyst Ike Boruchow maintains Levi Strauss (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEVI#NYSE">LEVI</a>) with a Overweight and raises the price target from $20 to $22.

LEVI

Wells Fargo Maintains Overweight on Levi Strauss, Raises Price Target to $22

B of A Securities analyst Kevin Fischbeck maintains Tenet Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) with a Buy and raises the price target from $165 to $180.

B of A Securities Maintains Buy on Tenet Healthcare, Raises Price Target to $180

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fguardianpharmacy.com&amp;esheet=54253228&amp;newsitemid=20250514975941&amp;lan=en-US&amp;anchor=Guardian+Pharmacy+Services%2C+Inc.&amp;index=1&amp;md5=62b919cf5bc614b0f1a9c765bbabf29b">Guardian Pharmacy Services, Inc.</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GRDN#NYSE">GRDN</a>), one of the nation's largest and most innovative long-term care (LTC) pharmacy services companies, today announced the acquisition of Senior Care Pharmacy in Wichita, Kan. The acquisition expands Guardian's operations into south central and southwest Kansas, strengthening its overall presence across the state and enabling it to bring its high-quality pharmacy services to residents in assisted living, skilled nursing and behavioral health communities, as well as individuals with intellectual and developmental disabilities in these newly served areas.
With the addition of the Wichita location, Guardian now operates two pharmacies in Kansas – Kansas City and Wichita – enhancing its ability to support LTC communities across the state. Pharmacist Michael Counts, president of Guardian's Kansas City pharmacy, will also lead the Wichita location. Senior Care Pharmacy will continue operating under its existing name, with its local leadership team and entire staff.
 &nbsp;

GRDN

Guardian Pharmacy Services Acquires Senior Care Pharmacy in Wichita, Kan, Expanding Midwest Long-Term Care Footprint; Terms Not Disclosed

<a href="https://www.aerotime.aero/articles/qatar-airways-boeing-agreement-trump" title="https://www.aerotime.aero/articles/qatar-airways-boeing-agreement-trump">https://www.aerotime.aero/articles/qatar-airways-boeing-agreement-trump</a>

Contracts

Global

'Qatar Airways Expected To Order 150 Boeing Jets During Donald Trump's Doha Visit' - AeroTime

Shares of Quoin Pharmaceuticals Ltd &#8211; ADR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNRX#NASDAQ">QNRX</a>) surged 31.1% to $8.34 on Wednesday morning following the release of promising initial data from its <a href="https://www.benzinga.com/pressreleases/25/05/g45403010/quoin-pharmaceuticals-announces-initial-positive-clinical-data-for-qrx003-from-pediatric-peeling-s">ongoing clinical study</a> of QRX003 for Pediatric Peeling Skin Syndrome.
What To Know: After 12 weeks of treatment, the single enrolled patient showed significant improvements across key clinical measures. The Modified Ichthyosis Area Severity Index dropped from 36 to 12, while the Investigator's Global Assessment (IGA) improved from "severe" to "mild." 
Additionally, the Children's Dermatology Life Quality Index score improved from 19 to 11, indicating a better quality of life. QRX003 was <a href="https://www.benzinga.com/pressreleases/25/05/g45403010/quoin-pharmaceuticals-announces-initial-positive-clinical-data-for-qrx003-from-pediatric-peeling-s">well tolerated</a>, with no adverse events reported, and the patient is expected to continue treatment with further evaluation planned at 24 weeks. 
Quoin CEO Dr. Michael Myers called the two-grade improvement in severity "clinically meaningful" and emphasized QRX003's potential as the first approved therapy for this rare disease. The company says it is also continuing to advance QRX003 in late-stage trials for Netherton Syndrome.
Read Also: <a href="https://www.benzinga.com/trading-ideas/movers/25/05/45405793/red-cat-holdings-stock-is-ripping-higher-wednesday-whats-going-on">Red Cat Holdings Stock Is Ripping Higher Wednesday: What&#8217;s Going On?</a>
<h2 class="wp-block-heading">How To Buy QNRX Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Quoin Pharmaceuticals&#8217; case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, QNRX has a 52-week high of $54.95 and a 52-week low of $5.01.

QNRX

Why Quoin Pharmaceuticals (QNRX) Stock Is Exploding Higher Wednesday

Wells Fargo analyst Ike Boruchow maintains Kontoor Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KTB#NYSE">KTB</a>) with a Overweight and raises the price target from $85 to $90.

Wells Fargo Maintains Overweight on Kontoor Brands, Raises Price Target to $90

KRMN

KRMN stock has given up its prior gain. Karman Holdings shares were trading higher after the company reported better-than-expected Q1 financial results.

Cantor Fitzgerald analyst Olivia Brayer assumes Vanda Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VNDA#NASDAQ">VNDA</a>) with a Overweight rating and announces Price Target of $13.

Initiation

VNDA

Cantor Fitzgerald Assumes Vanda Pharmaceuticals at Overweight, Announces Price Target of $13

Wells Fargo analyst Ike Boruchow maintains Hanesbrands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HBI#NYSE">HBI</a>) with a Underweight and raises the price target from $3 to $4.

Wells Fargo Maintains Underweight on Hanesbrands, Raises Price Target to $4

Banzai International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNZI#NASDAQ">BNZI</a>) is set to give its latest quarterly earnings report on Thursday, 2025-05-15. Here's what investors need to know before the announcement.
Analysts estimate that Banzai International will report an earnings per share (EPS) of $-4.00. 
The market awaits Banzai International's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Performance in Previous Earnings</h3>
The company's EPS beat by $7.85 in the last quarter, leading to a 13.11% drop in the share price on the following day.
Here's a look at Banzai International's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-8</td>
<td>-4.50</td>
<td>-6.5</td>
<td></td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.15</td>
<td>-0.46</td>
<td>-7.5</td>
<td>-13</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-13.0%</td>
<td>-11.0%</td>
<td>-2.0%</td>
<td>-1.0%</td>
</tr>
</tbody>
</table>

<h3>Tracking Banzai International's Stock Performance</h3>
Shares of Banzai International were trading at $0.9993 as of May 13. Over the last 52-week period, shares are down 93.42%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/BNZI/earnings">To track all earnings releases for Banzai International visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Comments

Tema Electrification ETF

Notizie

Ultime notizie per Tema Electrification ETF (NASDAQ:VOLT)

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO